EGFR及KRAS基因突变与非小细胞肺癌临床病理特征的关系

发布时间：2018-06-09 01:53

本文选题：肺肿瘤 + 非小细胞肺癌　；参考：《临床与实验病理学杂志》2017年04期

【摘要】：目的探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者EGFR及KRAS基因突变与其临床病理特征的关系。方法采用毛细管电泳法及荧光探针法分别检测64例NSCLC组织中EGFR及KRAS基因的突变类型。结果 64例NSCLC中发生EGFR基因突变27例(占42.2%)、KRAS基因突变8例(占12.5%),同时发生EGFR和KRAS基因突变者4例(占6.25%)。EGFR基因突变与患者性别、组织学类型及吸烟史有关(P0.05),与患者年龄、分化程度、有无淋巴结转移及TNM分期无关(P0.05)。肺腺癌中KRAS基因突变率明显高于肺鳞癌(P0.01),KRAS基因突变与患者性别、年龄、有无吸烟史、分化程度、有无淋巴结转移及TNM分期均无关(P0.05)。结论 NSCLC患者中EGFR基因突变率高于KRAS基因突变率,EGFR突变率在女性、肺腺癌、不吸烟患者中较高,KRAS基因突变率在腺癌患者中较高,且EGFR和KRAS基因突变可以同时发生。
[Abstract]:Objective to investigate the relationship between the mutations of EGFR and KRAS genes and their clinicopathological features in patients with non-small cell lung cancer (NSCLC). Methods the mutation types of EGFR and KRAS genes in 64 NSCLC tissues were detected by capillary electrophoresis and fluorescence probe respectively. Results among 64 NSCLC patients, 27 cases (42.2%) had EGFR gene mutation (42.2%), 8 cases (12.5%) had KRAS gene mutation, 4 cases (6.25%) had EGFR and KRAS gene mutation (6.25%). The degree of differentiation, lymph node metastasis and TNM staging were not significant (P 0.05). The mutation rate of KRAS gene in lung adenocarcinoma was significantly higher than that in squamous cell carcinoma (P 0.01). There was no correlation between KRAS gene mutation and sex, age, smoking history, differentiation degree, lymph node metastasis and TNM stage. Conclusion the mutation rate of EGFR gene in NSCLC patients is higher than that of KRAS gene mutation. The mutation rate of EGFR gene is higher in female, lung adenocarcinoma and non-smoking patients, and EGFR and KRAS gene mutations can occur at the same time.
【作者单位】：华北理工大学附属医院病理科;
【基金】：河北省临床医学优秀人才培养和基础课题研究项目(361036)
【分类号】：R734.2

【相似文献】